You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

380 Results
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Adjuvant, Curative
Feb 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Drugs Used:
pentostatin (Unfunded),
alemtuzumab (Compassionate)
Apr 2021
Regimen
Cancer Type:
Skin, 
Basal Cell
Intent: Palliative
Apr 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
ODB - General Benefit
    etoposide - oral capsules
Apr 2021
Guidelines and Advice
Status: Current
ID: ES 30-1
Mar 2021
Cancer facts
Guidelines and Advice
Jun 2021
Guidelines and Advice
Guidelines and Advice
Jun 2021

Pages